SOUTH SAN FRANCISCO, Calif., Nov. 25 /PRNewswire/ -- Proteolix, Inc., a leader in the discovery and development of novel therapeutics that target protein degradation pathways in cancer and autoimmune diseases, today announced that data from two ongoing Phase 2 clinical trials of carfilzomib in multiple myeloma will be presented at the upcoming 50th Annual Meeting of the American Society of Hematology (ASH). Carfilzomib is the first in a new class of specific proteasome inhibitors and is currently in multiple clinical trials for hematologic malignancies and solid tumors. This year's ASH conference will be held December 6-9, 2008 at the George Moscone Center in San Francisco, California.
Sundar Jagannath, M.D., Chief of the Multiple Myeloma Program, Bone Marrow
and Blood Stem Cell Transplantation at St. Vincent's Comprehensive Cancer
Center in New York will present initial results from Proteolix's Phase 2 study
of carfilzomib for the treatment of patients with relapsed and refractory
multiple myeloma during the Novel Therapies for Myeloma and Related Disorders
session at 7:00 a.m. on Tuesday, December 9, 2008. This ongoing Phase 2 trial
is an open-label multi-center study of single-agent carfilzomib in patients
who have previously failed at least two prior treatments, containing
bortezomib and either lenalidomide or thalidomide, and are refractory to their
last treatment. Data from a second ongoing Phase 2 clinical trial of
single-agent carfilzomib in relapsed multiple myeloma patients (stratified by
prior therapy with bortezomib) will be presented immediately thereafter at
7:15 a.m. by Ravi Vij, M.D., Associate Professor of Medicine, Division of
Oncology, Section of Bone Marrow Transplantation,
In addition to the oral presentations, the company will have several poster presentations highlighting the results of preclinical studies that further characterize the mechanism and safety profile of carfilzomib. Proteolix will also have a poster presentation on the preclinical pharmacology and characterization of its oral proteasome inhibitor known as PR-047.
A complete list of the company's oral and poster presentations at the ASH meeting follows:
Oral Presentations -- Tuesday, December 9, 2008 Session: Novel Therapies for Myeloma and Related Disorders -- 7:00 a.m. PST: Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM) (Abstract #864) -- 7:15 a.m. PST: Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM) (Abstract #865) Location: Moscone Center, Gateway Ballroom 103-South Poster Presentations Sunday, December 7, 2008, 6:00 p.m. -- 8:00 p.m. PST Session: Molecular Pharmacology, Drug Resistance Poster II -- Non-Proteasomal Targets of Proteasome Inhibitors Bortezomib and Carfilzomib (Abstract #2657) Session: Myeloma -- Pathophysiology and Preclinical Studies Excluding Therapy Poster II -- The Selective Proteasome Inhibitor Carfilzomib is Well Tolerated in Experimental Animals with Dose Intensive Administration (Abstract #2765) Location: Moscone Center Hall A Monday, December 8, 2008, 5:30 p.m. -- 7:30 p.m. PST Session: Myeloma -- Pathophysiology and Preclinical Studies Excluding Therapy Poster III -- Induction of Sustained Early G1 Arrest by Selective Inhibition of CDK4 and CDK6 Primes Myeloma Cells for Synergistic Killing by Proteasome Inhibitors Carfilzomib and PR-047 (Abstract #3670) -- Preclinical Pharmacology and in vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome (Abstract #3671) Location: Moscone Center Hall A
Proteolix, Inc. is a privately-held biopharmaceutical company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib (PR-171), the first in a new class of highly specific proteasome inhibitors, is currently in multiple Phase 2 clinical studies to evaluate its safety and efficacy in hematologic and solid tumor malignancies. Proteolix is also developing a pipeline of novel proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor. For additional information on Proteolix, please visit http://www.proteolix.com.
Contact information Investors: Media Inquiries: Matthew Ferguson BCC Partners Chief Financial Officer Karen L. Bergman or Michelle Corral 650-266-2825 650-575-1509 or 415-794-8662 email@example.com
|SOURCE Proteolix, Inc.|
Copyright©2008 PR Newswire.
All rights reserved